Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial

Abstract Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with type 2 diabetes (T...

Полное описание

Библиографические подробности

Главные авторы:	David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren S. Lund
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2024-07-01
Серии:	Cardiovascular Diabetology
Предметы:	Diabetes mellitus Type 2 Myocardial infarction Sodium-glucose transporter 2 inhibitors
Online-ссылка:	https://doi.org/10.1186/s12933-024-02328-6
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!